Gufic Biosciences Limited (IN:GUFICBIO)
:GUFICBIO
Want to see IN:GUFICBIO full AI Analyst Report?
Top Page
Gufic Biosciences Limited
(GUFICBIO)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹295.00
▼(-12.76% Downside)
Action:ReiteratedDate:11/22/25
Gufic Biosciences' overall stock score is primarily influenced by its strong financial performance, despite challenges in cash flow and debt management. Technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Consistent Revenue Growth
Sustained revenue expansion indicates durable demand and successful market penetration across formulations. Over multiple years rising top-line supports reinvestment in capacity, funds R&D and scale benefits, and underpins long-term margin sustainability even if profitability lags episodically.
Negative Factors
Elevated Leverage
Moderate-to-high debt levels raise long-term financing risk and increase interest expense sensitivity to rate moves. Persistent leverage constrains strategic flexibility, heightens refinancing risk during downturns, and limits capacity to fund organic investment without deleveraging.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sustained revenue expansion indicates durable demand and successful market penetration across formulations. Over multiple years rising top-line supports reinvestment in capacity, funds R&D and scale benefits, and underpins long-term margin sustainability even if profitability lags episodically.
Read all positive factors
Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹28.60B
Dividend Yield0.03%
Average Volume (3M)2.36K
Price to Earnings (P/E)67.8
Beta (1Y)0.72
Revenue Growth9.88%
EPS Growth-40.57%
CountryIN
Employees1,491
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.24
Shares Outstanding100,282,510
10 Day Avg. Volume2,111
30 Day Avg. Volume2,356
Financial Highlights & Ratios
PEG Ratio-2.39
Price to Book (P/B)5.63
Price to Sales (P/S)4.13
P/FCF Ratio124.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Gufic Biosciences Limited Business Overview & Revenue Model
Company Description
Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppr...
How the Company Makes Money
null...
Gufic Biosciences Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.74B | 8.20B | 8.07B | 6.91B | 7.79B | 4.88B |
| Gross Profit | 4.41B | 2.97B | 4.07B | 3.51B | 3.56B | 2.31B |
| EBITDA | 1.37B | 1.38B | 1.48B | 1.37B | 1.48B | 857.85M |
| Net Income | 569.19M | 696.50M | 861.36M | 797.05M | 958.40M | 442.32M |
Balance Sheet | ||||||
| Total Assets | 12.71B | 11.69B | 10.93B | 8.61B | 5.21B | 3.92B |
| Cash, Cash Equivalents and Short-Term Investments | 880.79M | 290.22M | 11.37M | 286.02M | 116.08M | 62.01M |
| Total Debt | 3.69B | 3.36B | 3.33B | 3.34B | 643.87M | 615.37M |
| Total Liabilities | 6.40B | 5.68B | 5.60B | 5.13B | 2.52B | 2.19B |
| Stockholders Equity | 6.31B | 6.01B | 5.33B | 3.48B | 2.69B | 1.73B |
Cash Flow | ||||||
| Free Cash Flow | 434.82M | 270.96M | -1.20B | -2.14B | 187.86M | 748.51M |
| Operating Cash Flow | 591.15M | 1.03B | -74.57M | -265.87M | 1.06B | 872.51M |
| Investing Cash Flow | -152.90M | -717.09M | -1.02B | -1.91B | -945.89M | -66.93M |
| Financing Cash Flow | 150.53M | -163.26M | 823.81M | 2.34B | -62.44M | -786.18M |
Gufic Biosciences Limited Technical Analysis
Neutral
338.15
Price Trends
292.89
Positive
314.42
Negative
336.30
Negative
Market Momentum
3.39
Negative
55.45
Neutral
79.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Neutral. The current price of 338.15 is above the 20-day moving average (MA) of 293.28, above the 50-day MA of 292.89, and above the 200-day MA of 336.30, indicating a neutral trend. The MACD of 3.39 indicates Negative momentum. The RSI at 55.45 is Neutral, neither overbought nor oversold. The STOCH value of 79.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GUFICBIO.
Gufic Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₹27.65B | 29.38 | ― | 0.97% | 8.37% | 19.15% | |
57 Neutral | ₹28.60B | 67.80 | ― | 0.03% | 9.88% | -40.57% | |
57 Neutral | ₹22.69B | 20.54 | ― | 0.49% | 1.02% | -24.31% | |
55 Neutral | ₹23.41B | -118.51 | ― | 0.58% | -4.17% | -117.43% | |
54 Neutral | ₹31.88B | -76.20 | ― | ― | -10.02% | -82.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹19.37B | -18.14 | ― | 0.08% | 1.96% | -970.01% |
* Healthcare Sector Average
IN:GUFICBIO
Gufic Biosciences Limited
285.20
-75.05
-20.83%
IN:HIKAL
Hikal Limited
189.85
-207.03
-52.16%
IN:INDOCO
Indoco Remedies Limited
209.90
-19.69
-8.58%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
94.20
30.78
48.53%
IN:MOREPENLAB
Morepen Laboratories Limited
41.41
-17.59
-29.81%
IN:ORCHPHARMA
Orchid Pharma Limited
628.50
-165.50
-20.84%
Gufic Biosciences Limited Corporate Events
Gufic Biosciences Settles SEBI Compliance Penalties Over Independent Director Appointment
Mar 13, 2026
Gufic Biosciences has disclosed that stock exchanges BSE and NSE imposed monetary penalties for alleged non-compliance with SEBI rules governing the appointment of independent directors over the age of 75. The issue relates to the appointment of K...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.